Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

446 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective α7 nicotinic receptor partial agonist, in single ascending-dose and bioavailability studies.
Barbier AJ, Hilhorst M, Van Vliet A, Snyder P, Palfreyman MG, Gawryl M, Dgetluck N, Massaro M, Tiessen R, Timmerman W, Hilt DC. Barbier AJ, et al. Among authors: van vliet a. Clin Ther. 2015 Feb 1;37(2):311-24. doi: 10.1016/j.clinthera.2014.09.013. Epub 2014 Oct 14. Clin Ther. 2015. PMID: 25438724 Free article. Clinical Trial.
Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial.
Tiessen RG, Kennedy CA, Keller BT, Levin N, Acevedo L, Gedulin B, van Vliet AA, Dorenbaum A, Palmer M. Tiessen RG, et al. Among authors: van vliet aa. BMC Gastroenterol. 2018 Jan 5;18(1):3. doi: 10.1186/s12876-017-0736-0. BMC Gastroenterol. 2018. PMID: 29304731 Free PMC article. Clinical Trial.
Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
O'Farrell AM, van Vliet A, Abou Farha K, Cherrington JM, Campbell DA, Li X, Hanway D, Li J, Guler HP. O'Farrell AM, et al. Among authors: van vliet a. Clin Ther. 2007 Aug;29(8):1692-705. doi: 10.1016/j.clinthera.2007.08.005. Clin Ther. 2007. PMID: 17919550 Clinical Trial.
Rapid decline of viral RNA in chronic hepatitis C patients treated once daily with IDX320: a novel macrocyclic HCV protease inhibitor.
de Bruijne J, van Vliet A, Weegink CJ, Mazur W, Wiercinska-Drapało A, Simon K, Cholewińska-Szymańska G, Kapocsi J, Várkonyi I, Zhou XJ, Temam MF, Molles J, Chen J, Pietropaolo K, McCarville JF, Sullivan-Bólyai JZ, Mayers D, Reesink H. de Bruijne J, et al. Among authors: van vliet a. Antivir Ther. 2012;17(4):633-42. doi: 10.3851/IMP2078. Epub 2012 Mar 16. Antivir Ther. 2012. PMID: 22427481 Clinical Trial.
446 results